Burning Rock Biotech Limited Share Price

Equities

BNR

US12233L2060

Healthcare Facilities & Services

Delayed Nasdaq 16:54:08 20/05/2024 BST 5-day change 1st Jan Change
8.121 USD -2.15% Intraday chart for Burning Rock Biotech Limited +0.89% -12.67%

Financials

Sales 2022 563M 77.86M 6.13B Sales 2023 537M 74.29M 5.85B Capitalization 696M 96.21M 7.57B
Net income 2022 -971M -134M -10.57B Net income 2023 -654M -90.41M -7.12B EV / Sales 2022 1.38 x
Net cash position 2022 857M 118M 9.32B Net cash position 2023 616M 85.18M 6.71B EV / Sales 2023 0.15 x
P/E ratio 2022
-1.66 x
P/E ratio 2023
-1.03 x
Employees 786
Yield 2022 *
-
Yield 2023
-
Free-Float 62.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.15%
1 week+0.89%
Current month+7.55%
1 month-5.57%
3 months-2.72%
6 months-9.86%
Current year-12.67%
More quotes
1 week
7.53
Extreme 7.53
8.99
1 month
7.28
Extreme 7.28
8.99
Current year
5.72
Extreme 5.722
9.99
1 year
5.72
Extreme 5.722
29.20
3 years
5.72
Extreme 5.722
386.40
5 years
5.72
Extreme 5.722
397.50
10 years
5.72
Extreme 5.722
397.50
More quotes
Managers TitleAgeSince
Founder - 31/12/13
Chief Executive Officer 46 31/12/13
Director of Finance/CFO 40 31/12/18
Members of the board TitleAgeSince
Director/Board Member 61 31/07/16
Chief Executive Officer 46 31/12/13
Director/Board Member 53 31/05/14
More insiders
Date Price Change Volume
20/05/24 8.121 -2.15% 3 417
17/05/24 8.3 +3.36% 6,594
16/05/24 8.03 -2.43% 5,845
15/05/24 8.23 +2.88% 5,921
14/05/24 8 -0.62% 4,768

Delayed Quote Nasdaq, May 20, 2024 at 04:54 pm

More quotes
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
More about the company